Kazia posts 86% tumor drop in TNBC case

Kazia Therapeutics Limited filed a Form 6-K to furnish a press release describing an 86% reduction in tumor burden in an expanded-access case of a metastatic triple-negative breast cancer (TNBC) patient treated with a paxalisib-immunotherapy regimen.

Rhea-AI Filing Summary

Kazia Therapeutics Limited filed a Form 6-K to furnish a press release describing an 86% reduction in tumor burden in an expanded-access case of a metastatic triple-negative breast cancer (TNBC) patient treated with a paxalisib-immunotherapy regimen. The press release, dated October 2, 2025, is attached as Exhibit 99.1.

The company is also incorporating the information in this report, including Exhibit 99.1 but excluding the quoted remarks from its Chief Executive Officer, into its existing Form F-3 registration statement (File No. 333-281937). This links the clinical case update to the company’s broader capital-raising framework.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kazia Therapeutics (KZIA) report in this Form 6-K?

Kazia Therapeutics reported that it issued a press release describing an 86% reduction in tumor burden in an expanded-access case of a metastatic TNBC patient treated with a paxalisib-immunotherapy regimen, and furnished that release as Exhibit 99.1.

How is the 86% tumor reduction result being used by Kazia Therapeutics (KZIA)?

Kazia is incorporating by reference the information in this report, including Exhibit 99.1 but excluding the CEO’s quote, into its Form F-3 registration statement (File No. 333-281937).

What is attached as Exhibit 99.1 to Kazia Therapeutics’ Form 6-K?

Exhibit 99.1 is a press release dated October 2, 2025 titled “Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen.”

Does this Form 6-K include financial or earnings data for Kazia Therapeutics (KZIA)?

No. The Form 6-K focuses on furnishing a clinical-case press release and its incorporation into a Form F-3 registration statement; it does not present financial or earnings figures.

Whose statement is excluded from incorporation into the Form F-3 registration statement?

The filing specifies that the quote of Dr. John Friend, Chief Executive Officer of Kazia Therapeutics, contained in Exhibit 99.1 is not incorporated into the Form F-3 registration statement.

Who signed Kazia Therapeutics’ October 2025 Form 6-K?

The Form 6-K was signed on behalf of Kazia Therapeutics Limited by John Friend, its Chief Executive Officer, dated October 2, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/02/2025 - 08:55 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2025

Commission File Number 000-29962

Kazia Therapeutics Limited

(Translation of registrant’s name into English)

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On October 2, 2025, Kazia Therapeutics Limited (the “Company”) issued a press release titled “Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen.” A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote of Dr. John Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Company’s registration statement on Form F-3 (File No. 333-281937).

EXHIBIT LIST

Exhibit		Description
99.1		Press Release of Kazia Therapeutics Limited dated October 2, 2025

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Kazia Therapeutics Limited (Registrant)

/s/ John Friend

John Friend

Chief Executive Officer

Date: October 2, 2025